The domestic special medicine for diabetes will soon be on the market.

This article discusses the knowledge points related to the upcoming launch of a domestic diabetes special drug, hoping to be helpful to everyone. Don't forget to bookmark this site. The specific time for the launch of the Hualing new drug has not yet been announced. Chen Li, the founder, CEO, and chief scientific officer of Hualing Pharmaceuticals, stated that after the new diabetes oral innovative drug, glucose kinase activator Dorzagliatin, was accepted for new drug application (NDA) by the China National Medical Products Administration in April, it is expected to be approved for market launch in the first quarter of next year, based on the estimated approval time of about 200 working days for innovative diabetes drugs.

I. Hualing Pharmaceuticals Hualing Pharmaceuticals is the world's first company to achieve clinical development of a glucose kinase activator (GKA) for blood glucose sensors, and has established technical standards and clinical medication plans for "repairing sensing, reshaping stability, and fundamentally treating diabetes." It has achieved a breakthrough in the global first-in-class diabetes drug in China. On April 23rd, Hualing Pharmaceuticals announced that the NDA application for the first-in-class diabetes drug Dorzagliatin had been accepted by the National Medical Products Administration New Drug Evaluation Center. Dorzagliatin became the first glucose kinase activator class diabetes treatment drug to submit a new drug application for market approval globally, and is expected to be the first-in-class new drug to be launched in China.

II. Not only a monotherapy application This application is not only for Dorzagliatin as a monotherapy, but also for its combination therapy with metformin, which has completed clinical trials and has been included in the application. Chen Li stated that since the mechanism of Dorzagliatin stands at the "top of the pyramid," theoretically it can be used in combination with the mainstream drugs currently used for diabetes treatment. Hualing Pharmaceuticals has already completed combination therapy trials of Dorzagliatin with Ertugliflozin and Saxagliptin, which have shown significant synergistic effects. Clinical trials of combination therapy with GLP-1 receptor agonists, insulin, and others are also planned.

Hualing Pharmaceuticals Technology (Shanghai) Co., Ltd. is a biotechnology company based in China with a global perspective. It was established in Zhangjiang, Shanghai in 2011 and listed in Hong Kong in 2018. Hualing Pharmaceuticals adheres to the principles of "putting patients first, innovation as the foundation, and good medicine for the people," and creates a collaborative innovation model of "integrating Chinese and Western medicine, and sharing and winning together." It insists on the management principles of "high standards, high quality, and creating high value" to achieve "global first-in-class, China's first launch."

The National Medical Products Administration approved the listing of Dapagliflozin tablets. Will this be a "savior" for diabetics? Yes, this medication can improve blood sugar levels in diabetic patients and help control their blood sugar levels. It is indeed a savior for diabetics. Born in Shanghai! The world's first innovative diabetes drug has been approved for listing, but it has also experienced many obstacles during the research process...

During the research process, many difficulties were encountered. Moreover, many obstacles were encountered during the research process, and there were also cases of material shortage. Research and development issues were also encountered, as well as issues with preservation. However, China's researchers have successfully overcome these difficulties. A groundbreaking new diabetes drug has been approved for market, which may bring about a major change in the trillion-yuan blood sugar lowering track. What is the investment logic?

Its main logic lies in the fact that there are still quite a large number of diabetes patients in our country, and these patients will continue to take relevant medications. World's first! This new blood sugar-lowering drug has been approved in China, diabetes is no longer an incurable disease... Recently, a globally innovative blood sugar-lowering drug was born in Shanghai. It is said that this drug can alleviate diabetes from the source and improve patients' ability to regulate blood sugar autonomously. However, the status of diabetes as an incurable disease has not been shaken. This drug only alleviates the development of complications in diabetic patients, thus controlling the condition.

How does diabetes develop? Diabetes is caused by various factors, and it manifests as systemic metabolic disorders of carbohydrate, fat, and protein metabolism, characterized by chronic hyperglycemia, with insufficient insulin secretion, impaired insulin action, or both. Firstly, there may be impaired pancreatic islet secretion or insulin resistance, but blood sugar levels will not increase significantly. Then, there will be compensation failure of pancreatic islet function, leading to elevated postprandial blood sugar and persistently high fasting blood sugar, known as prediabetes. In addition, there is asymptomatic diabetes, which gradually presents symptoms such as polyuria, polydipsia, polyphagia, and weight loss. Finally, if diabetes is not effectively controlled for a long period, a series of diabetes complications such as kidney disease, retinopathy, and neuropathy may occur.

Diabetic patients need to control their diet. Dietary control is extremely important for diabetic patients, whether they have type 1 or type 2 diabetes. Patients should follow a low-calorie diet as individual differences in daily calorie requirements vary and cannot be based on others' dietary standards. Food should be diverse, especially grains such as oats, buckwheat, cornmeal, etc., which are rich in B vitamins, various trace elements, and dietary fiber, making them very suitable as staple foods for diabetic patients.

Exercise can effectively control the development of diabetes. Many people with diabetes are overweight, and they experience shortness of breath and chest tightness with even a little exercise, so many people do not like to exercise. In fact, for diabetes patients, if they persist in exercising, not only will it increase the consumption of sugar, but it will also increase the sensitivity of insulin receptors to insulin. Therefore, exercise can help diabetes patients better control blood sugar. Maintaining exercise on the basis of controlling diet is very helpful for controlling complications of diabetes.

The above is the explanation given by the editor about the upcoming release of domestically produced special drugs for diabetes. If you wish to learn more about the upcoming release of domestically produced special drugs for diabetes and other related information, please follow and bookmark our website.